Skip to main navigation Skip to search Skip to main content

Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity

  • Mark J. Shelton
  • , Ross G. Hewitt
  • , John M. Adams
  • , Steve R. Cox
  • , James H. Chambers
  • , Gene D. Morse
  • GlaxoSmithKline
  • SUNY Buffalo
  • PharmaResearch Corporation
  • Pfizer

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

To determine the impact of gastric hypoacidity and acidic beverages on delavirdine mesylate pharmacokinetics in HIV-infected subjects, matched subjects with (n = 11) and without (n = 10) gastric hypoacidity received delavirdine 400 mg tid with either water or an acidic beverage (usually orange juice). The pharmacokinetics of delavirdine and its N-desalkyl metabolite were determined over 8 hours after 14 days of each treatment. Gastric pH was measured at baseline and during each pharmacokinetic evaluation. Delavirdine exposure (Cmax, AUC0→8h, and Cmin) was ≈ 50% lower and the extent of delavirdine metabolism was higher in subjects with gastric hypoacidity. Orange juice produced a lower mean gastric pH compared to water and increased delavirdine absorption by 50% to 70% in subjects with gastric hypoacidity. However, orange juice had a marginal impact on delavirdine exposure in subjects without gastric hypoacidity. HIV-infected subjects with gastric hypoacidity significantly mulabsorb delavirdine. Delavirdine administration with acidic beverages improves, but does not normalize, absorption in these subjects.

Original languageEnglish
Pages (from-to)171-179
Number of pages9
JournalJournal of Clinical Pharmacology
Volume43
Issue number2
DOIs
StatePublished - Feb 1 2003

Fingerprint

Dive into the research topics of 'Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity'. Together they form a unique fingerprint.

Cite this